David Mutimer
About
In The Last Decade
David Mutimer
150 papers receiving 5.6k citations
Hit Papers
Peers
Comparison fields: 5 of 112
- Hepatology 4.8k
- Epidemiology 4.7k
- Infectious Diseases 845
- Surgery 660
- Pharmacology 224
Countries citing papers authored by David Mutimer
This map shows the geographic impact of David Mutimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Mutimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Mutimer more than expected).
Fields of papers citing papers by David Mutimer
This network shows the impact of papers produced by David Mutimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Mutimer. The network helps show where David Mutimer may publish in the future.
Co-authorship network of co-authors of David Mutimer
This figure shows the co-authorship network connecting the top 25 collaborators of David Mutimer. A scholar is included among the top collaborators of David Mutimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Mutimer. David Mutimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 8 | |
| 3 | 7 | |
| 4 | 18 | |
| 5 | OUTCOMES OF PATIENTS INTERRUPTING GLECAPREVIR/PIBRENTASVIR TREATMENT: A CASE SERIES FROM CLINICAL TRIALS | 2 |
| 6 | 18 | |
| 7 | Scavenger receptor B-I antagonist ITX5061 modulates early HCV kinetics in patients undergoing liver transplantation: results of a phase Ib clinical trial | 1 |
| 8 | 23 | |
| 9 | 120 | |
| 10 | 34 | |
| 11 | 6 | |
| 12 | 7 | |
| 13 | 50 | |
| 14 | 31 | |
| 15 | 37 | |
| 16 | 28 | |
| 17 | 53 | |
| 18 | 13 | |
| 19 | 7 | |
| 20 | LOW PREVALENCE OF ACTIVATING K-RAS GENE-MUTATIONS IN HUMAN HEPATOCARCINOGENESIS | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.